Fact CheckerSign in

NCT05799690Active, not recruiting

Comparison of Different Rehabilitation Protocols in Parkinson's Disease With Postural Instability and Gait Disorders

Multiparametric Biomarkers to Predict the Response to Different Protocols of Motor-cognitive Rehabilitation in Parkinson's Disease Subjects With Postural Instability and Gait Disorders

Source: ClinicalTrials.gov · Last updated 9 Mar 2026

Brief summary (registry, in English)

The aim of the study is to compare the effects of 2 different dosages and modalities of motor-cognitive rehabilitation in Parkinson's disease with postural instability and gait disorders (PD-PIGD) on clinical features, neuroimaging and blood-based biomarkers at short-term (2 months) and long-term (7 months) follow-up. Fifty subjects with PD-PIGD will be randomized in 2 training groups: DUAL-TASK+AOT-MI and the DUAL-TASK groups. The DUAL-TASK+AOT-MI group will perform a dual-task gait/balance training consisting of action observation training (AOT) and motor imagery (MI) combined with practicing the observed-imagined exercises; DUAL-TASK group will perform the same exercises combined with watching landscape videos. The training will last 6 weeks, 3 times/week, 1 hour per session. Before and after training (W6), all the patients will undergo neurological, gait/balance, cognitive/behavioral, magnetic resonance imaging (MRI) and serum biomarkers evaluations. Neurological, gait/balance, cognitive/behavioral assessments and serum biomarkers will be also repeated at the 14-week follow-up (W14) to assess maintenance of results. Patients of both DUAL-TASK+AOT-MI and DUAL-TASK groups will be further randomized to repeat the training (6 weeks, 3 times/week, 1 hour each session) starting at W14 (DUAL-TASK+AOT-MI\_DOUBLE and DUAL-TASK\_DOUBLE groups). After six weeks (W20) all the subjects repeating the training will be evaluated (neurological, gait/balance, cognitive/behavioral assessments). At 28-week follow-up (W28), the whole sample of patients will be assessed with neurological, gait/balance, cognitive/behavioral, MRI and serum biomarkers evaluations. All MRI scans will be acquired at least 12 hours after last dopaminergic therapy administration to mitigate the pharmacological effects on neural activity. Twenty age- and sex-matched healthy controls will be recruited to perform gait/balance and cognitive/behavioral assessments, blood sample and brain MRI acquisition at baseline. The secondary aims of the study are to define the neuroimaging and blood-based biomarkers of PD-PIGD patients presenting different clinical features (e.g. presence of mild cognitive impairment, freezing of gait, falls and mood disturbances) and to evaluate the role of blood-based and neuroimaging biomarkers, together with clinical characteristics, in predicting the response to different dosages of rehabilitation in PD-PIGD throughout the development of a machine-learning algorithm.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
80 (estimated)
First submitted
17 Mar 2023
Start date
30 Apr 2023
Primary completion date
30 Jul 2026
Lead sponsor
Prof. Massimo Filippi
NCT number
NCT05799690

What you commit to

  • Study type: Interventional
  • Planned participants: 80
  • From 30 Apr 2023 to the primary completion date, 30 Jul 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Medical conditions or substance abuse that could interfere with cognition;
  • Any major systemic, psychiatric, neurological, visual, and musculoskeletal disturbances or other causes of walking inability;
  • Brain damage at routine MRI, including lacunae and extensive cerebrovascular disorders;

Other

  • Contraindications to undergoing MRI examination;
  • Denied oral and written informed consent to study participation.

Who the study is looking for

  • 45 years ≤ age ≤ 85 years;
  • Idiopathic PD according to the Movement Disorders Society (MDS) diagnostic criteria
  • Hoehn \& Yahr (H\&Y) score \<= 4
  • PIGD phenotype
  • Stable dopaminergic medication for at least 4 weeks and without any changes during the observation period (28 weeks)
  • No dementia according to Litvan's criteria and Mini-Mental Status Examination score (MMSE) \>= 24
  • No significant tremor/involuntary movements that could determine artifacts during the MRI acquisition
  • Oral and written informed consent to study participation
  • sex-matched and age-matched (age range: mean age of PD years ± 15 years);
  • oral and written informed consent to study participation

Age in the registry: 45 years to 85 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
IRCCS San Raffaele
Coordinator of this site? Confirm its status
MilanItalyUnknown status
Neurology Unit, Azienda Ospedaliera Universitaria Integrata di Verona
Coordinator of this site? Confirm its status
VeronaItalyUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.